Effectiveness and duration of a second COVID-19 vaccine booster

Using a prospective national cohort of 3.75 million individuals aged 20 or older, we evaluated the effectiveness against COVID-19 related ICU admissions and death of mRNA-based second vaccine boosters for four different three-dose background regimes: BNT162b2 primary series plus a homologous booster, and CoronaVac primary series plus an mRNA booster, a homologous booster, and a ChAdOx-1 booster. We estimated the vaccine effectiveness weekly from February 14 to August 15, 2022, by estimating hazard ratios of immunization over non-vaccination, accounting for relevant confounders. The overall adjusted effectiveness of a second mRNA booster shot was 88.2% (95%CI, 86.2-89.9) and 90.5% (95%CI 89.4-91.4) against ICU admissions and death, respectively. Vaccine effectiveness showed a mild decrease for all regimens and outcomes, probably associated with the introduction of BA.4 and BA.5 Omicron sub-lineages and immunity waning. The duration of effectiveness suggests that no additional boosters are needed six months following a second booster shot.


Main text
The COVID-19 pandemic has caused more than 615 million cases and 6.5 million deaths reported globally as of September 2022. 1 COVID-19 vaccines have been essential to decrease the burden of disease and reduce restrictions associated with the pandemic response.A robust body of evidence showed that the primary series of several COVID-19 vaccines had high efficacy and effectiveness against symptomatic COVID-19 and severe illness in the first months. 2,3However, immunity waning and the emergence of new, highly transmissible SARS-CoV-2 lineages with increased immune evasion, lead many countries to roll out booster shots four to six months following the primary series. 4,5[8] The emergence and spread of the B. 1.1.5294][15][16][17] Policymakers need evidence on real-world effectiveness to guide vaccination policies.However, there is limited evidence for the effectiveness of second boosters, and it primarily refers to mRNA vaccines in Israel, Canada, and the USA among populations at higher risk (e.g., older adults and immunocompromised persons). 12,15,17Furthermore, there is no evidence of a potential waning of protection against COVID-19 for second boosters, or the effectiveness against severe disease of an additional booster dose for individuals who received their primary series based on inactivated vaccines, which constitute a considerable proportion of vaccinated individuals in low-and middle-income countries. 18sing a large prospective national observational cohort in Chile, we evaluated the effectiveness of mRNA-based second vaccine boosters for individuals with four different three-dose background regimes: (i) BNT162b2 primary series plus a homologous booster (3mRNA), (ii) CoronaVac primary series plus mRNA booster (CC+mRNA), (iii) CoronaVac primary series plus homologous booster (CCC), and (iv) CoronaVac primary series plus ChAdOx-1 booster (CCA).We estimated vaccine effectiveness weekly, from February 14, 2022, to August 15, 2022, against admission to an intensive care unit (ICU) and death (U07.1)associated with laboratory-confirmed SARS-CoV-2 infection.We estimated the overall vaccine effectiveness of an mRNA second booster, regardless of the three-dose background regimen, and for each group, using survival regression models to estimate hazard ratios of immunization (>13 days after the second dose) over non-vaccination, accounting for time-varying vaccination exposure and clinical, demographic, and socioeconomic confounders at baseline.The Chilean Ministry of Health launched the second booster campaign on February 14, 2022, based on a standard dose of Pfizer-BioNTech's BNT162b2 or Moderna's mRNA-1273 vaccines, prioritizing the elderly and immunocompromised individuals.By August 29, 2022, more than 10.6 million individuals had received an additional booster dose, representing 71.7% of the target population.Vaccination rollout and the health system in Chile have been described elsewhere. 19r study cohort included adults aged ≥20 years and affiliated with the Fondo Nacional de Salud (FONASA), the public national healthcare system, who completed a CoronaVac or BNT162b2's twodose primary series at least 120 days before the beginning of the follow-up on August 11, 2021, when the first-booster campaign was launched, and unvaccinated individuals.We excluded individuals with probable or confirmed COVID-19 according to reverse-transcription polymerase-chain-reaction assay for SARS-CoV-2 or antigen test reported before February 15, 2022 (Extended Fig. 1).Our final cohort included 3,754,785 adults.Of these, 2,623,802 (69.9) received a second booster shot of BNT162b2 or mRNA-1273 vaccine between February 14, 2022, and August 18, 2022, and 757,726 (20.2%) had not been vaccinated by the end of the follow-up.Vaccination rollout was organized through a publicly .available schedule and was free of charge (Extended Fig. 2).Notably, there was a high level of SARS-CoV-2 circulation during the rollout, in which the predominant Omicron sub-lineages were BA.2.1.12,BA.4, and BA.5 (Extended Fig.3).Cohort characteristics are described in Supplementary Material Tables 1-5.The incidence of COVID-19 and the vaccination status at the end of the follow-up differed significantly (P<0.001) by participant's sex, age group, comorbidities, nationality, region of residence, and income.
Our cohort represents a population immunized with various schemes of COVID-19 vaccines.Ninety-one percent of the cohort received a primary series of CoronaVac, combined with a first booster based on a viral-vectored (53%) or an mRNA vaccine (37%).The remaining participants (9%) received a primary series of CoronaVac and a first homologous or BNT162b2 mRNA vaccine booster.Similar to the overall effect of a second mRNA booster dose, the scheme-specific vaccine effectiveness of these boosters remained high by the end of the follow-up, ranging from 74.2% to 86.3% effectiveness against COVID-19-related ICU admission and 79.3% to 90.8% against death.The CCA vaccination scheme plus the additional mRNA booster dose provided the highest protection against COVID-19-related deaths.Our study was not designed to demonstrate the superiority of any specific vaccination scheme.However, our results suggest that mix-and-match strategies may provide comparable protection against severe disease to homologous, mRNA-based regimens.
Our findings are consistent with previous studies on second booster doses.A recent summary of studies on mRNA vaccines, 17 including eight studies from Israel, one from Canada, 12 and one from the USA, 15 all conducted during the Omicron outbreak, suggests that an additional mRNA booster enhances protection compared to three vaccine doses and unvaccinated individuals, particularly for severe outcomes.While not directly comparable, due to differences in study design, population characteristics, and outcome definitions, the studies in Canada 12 and the USA 15 estimate the vaccine effectiveness of an additional mRNA booster compared to unvaccinated individuals.The study in Canada, conducted among residents in long-term care facilities aged 60 years or older, found that the effectiveness of a fourth dose against severe outcomes was 87% (95%CI 82-90). 12In the USA, research was conducted among immunocompromised adults aged 50 years or older.Those results showed that the effectiveness of a fourth mRNA dose against hospitalization was 80% (95%CI 71-85).These studies have a relatively short follow-up time after the fourth dose, of two to ten weeks, and thus do not fully capture immunity waning.
. At least two other studies have examined the effectiveness of additional booster doses.A preprint study in Thailand examined the effectiveness of an additional booster dose based on Oxford-AstraZeneca's ChAdOx1 adenoviral vector vaccine among adults with various three-dose background regimes, including inactivated vaccines. 16The study found a vaccine effectiveness against symptomatic COVID-19 of 73% (95%CI 48-89) but did not examine its effectiveness against severe outcomes.Last, anecdotal evidence from two participants in a cohort of healthcare workers in the USA suggests that a second homologous mRNA booster may induce a substantial and durable neutralizing antibody response. 20r study has some limitations.As an observational study, there is a risk of selection bias if the vaccinated and unvaccinated groups differ in a systematic way, such as risk aversion, which affects the probability of exposure to the treatment and the risk of SARS-CoV-2 infection.We adjusted our estimates with observable clinical, demographic, and socioeconomic confounders that could affect vaccination and the risk of infection, but there could be residual confounding.Second, our study design did not allow us to separate the effect of immunity waning, and the emergence of new SARS-CoV-2 lineages with increased immune evasion on our vaccine effectiveness estimates against severe disease for an additional mRNA booster dose.Results should be interpreted with caution and in the context of Omicron.
Overall, our study shows that an additional booster dose with mRNA vaccine had high effectiveness against severe COVID-19, independent of the COVID-19 vaccine scheme received in the past.Overall protection against COVID-19-related ICU admission and death showed a moderate decrease of about 9% and 6%, respectively, by the end of the follow-up.The introduction of the BA.4 and BA.5 Omicron sublineages during the second part of the study period (Supplementary Material Figure 3) and immunity waning due to a decline in the circulating levels of neutralizing antibodies as described for primary series and first booster doses, may explain the decrease in protection.We provide evidence to support mRNAbased second boosters following various background COVID-19 vaccine schemes, including widely used inactivated vaccines.These results suggest that an additional booster would help minimize severe COVID-19, including deaths, and decrease the impact on the health system.The observed duration of .protection for a second booster dose suggests there may be longer-acting protection after repeated immunization with both homologous and heterologous schemes and that no additional boosters are needed at six months.

Exposures and outcomes
The Ministry of Health in Chile requires that all suspected COVID-19 cases are notified to health authorities through an online platform and undergo confirmatory laboratory testing.This is the source for the COVID-19 case count in this study.We assessed the effectiveness of mRNA-based second vaccine boosters for individuals with four different three-dose background regimes: (i) BNT162b2 primary series plus a homologous booster, (ii) CoronaVac primary series plus mRNA booster, (iii) CoronaVac primary series plus homologous booster, and (iv) CoronaVac primary series plus ChAdOx-1 booster.We estimated vaccine effectiveness weekly, from February 14, 2022, to August 15, 2022, against admission to an intensive care unit (ICU) and death (U07.1)associated with laboratory-confirmed SARS-CoV-2 infection.
We considered the onset of symptoms as a proxy for the time of infection.We used the time to the onset of symptoms from the beginning of the second booster campaign on February 14, 2022 as the endpoint of each outcome.Participants were classified into unvaccinated and fully immunized individuals (≥14 days after receipt of the additional mRNA booster dose).Individuals were excluded from the unvaccinated group when they received the first COVID-19 vaccine.We excluded the period between the first COVID-19 vaccine dose and 13 days after the additional mRNA booster dose from the at-risk person-time.

Statistical analyses
Descriptive data was compared using Pearson's χ 2 tests.2][23] We estimated vaccine effectiveness using the hazard ratio between treated and non-treated individuals.
Hazard ratios were adjusted for age, sex, region of residence, nationality, income, and comorbidities conditions (Supplementary Material Tables 1-5).We used a stratified version of the Cox hazards model 24 with time-dependent covariates to compare the risk of the event of interest between immunized and nonimmunized participants at each event time.Under the stratified Cox model, each combination of predictors has a specific hazard function that can evolve independently.
Let   be the time-to-event of interest, from February 14, 2022, for the i-th individual in the cohort,  = 1, … , .Let   ,  = 1, … , , be a p-dimensional vector of individual-specific characteristics, such as age and sex, and   () be the time-dependent treatment indicator.The model assumes that the time-toevents are independent and with probability distribution given by The time-to-event distribution is given by with   ∈ ℝ being the regression coefficient measuring the effectiveness of the  th treatment, and λ ,0 is the predictor-specific baseline hazard function, where    ,0 is the baseline probability distribution of the time-to-event in each strata.
We estimated the vaccine effectiveness as 100% • (1 −  {   }).We show the adjusted vaccine effectiveness results, including covariates as controls (age, gender, region, nationality, health insurance category, and comorbidities).We computed standard 95% Wald confidence intervals (95% CI) for the estimates.Inference was based on a partial likelihood approach. 25Each term in the partial likelihood of the effectiveness regression coefficient corresponds to the conditional probability of an individual expressing the outcome of interest from the risk set at a given calendar time.
We analyzed the data with the survival package 26 of R, version 4.0.5. 27e Comité Ético Científico Clínica Alemana Universidad del Desarrollo, Santiago, Chile, gave ethical approval for this research.The study was considered exempt from informed consent.
read and approved the final version of the manuscript.The authors vouch for the accuracy and completeness of the data and accept responsibility for publication.Drs.Jara, Cuadrado, and Araos contributed equally to the manuscript.primary series plus a homologous booster (3mRNA), a CoronaVac primary series plus (ii) mRNA booster (CC+mRNA), iii) homologous booster (CCC), or (iv) ChAdOx-1 booster (CCA), compared to unvaccinated individuals.Estimates were adjusted for time-varying vaccination exposure and clinical, demographic, and socioeconomic confounders at baseline (Supplementary Material Tables 1-5).≥

Figure 1 .
Figure 1.Overall vaccine effectiveness against COVID-19-related ICU admissions and death of mRNA-based second vaccine boosters for each week, March 7 through August 15, 2022.3mRNA denotes individuals who received a BNT162b2 primary series plus a homologous first booster dose.CC+mRNA, CCC, and CCA denote individuals with a primary series of CoronaVac plus a first mRNA, homologous, and a ChAdOx-1 first booster dose, respectively.

Table 1 .
Effectiveness against ICU admissions and death of mRNA-based second vaccine boosters in adults aged 20 years and older, February 14, 2022, through August 15, 2022*.coronavirus disease 2019.The Ministry of Health launched a COVID-19 vaccine first booster campaign on August 11, 2021, and a second booster campaign on February 14, 2022.The table shows the estimated vaccine effectiveness of mRNA-based second vaccine boosters for individuals with four different three-dose background regimes: i) BNT162b2 * *COVID-19 denotes

Table 2 .
Notes.*COVID-19 denotes coronavirus disease 2019.The Ministry of Health launched a COVID-19 vaccine first booster campaign in August 11, 2021, and a second booster campaign on February 14, 2022, prioritizing individuals with older age, immunocompromised, and those with comorbidities, including chronic kidney disease, diabetes, cardiovascular disease (hypertension, myocardial infarction), stroke, chronic obstructive pulmonary disease, hematological disease (lymphoma, leukemia, myeloma), autoimmune disease (rheumatoid arthritis, juvenile idiopathic arthritis, systemic lupus erythematosus), HIV, and Alzheimer's and other dementias.Our study cohort included adults aged 20 years or older affiliated to the Fondo Nacional de Salud (FONASA), Chile's national public health insurance program.Characteristics of the study cohort of adults aged 20 years or older affiliated to FONASA, with laboratory-confirmed COVID-19, unvaccinated and vaccinated individuals who received a BNT162b2 primary series plus a homologous booster (3mRNA) and an additional mRNA booster (fourth dose), August 11, 2021, through August 18, 2022* Notes.*COVID-19 denotes coronavirus disease 2019.The Ministry of Health launched a COVID-19 vaccine first booster campaign in August 11, 2021, and a second booster campaign on February 14, 2022, prioritizing individuals with older age, immunocompromised, and those with comorbidities, including chronic kidney disease, diabetes, cardiovascular disease (hypertension, myocardial infarction), stroke, chronic obstructive pulmonary disease, hematological disease (lymphoma, leukemia, myeloma), autoimmune disease (rheumatoid arthritis, juvenile idiopathic arthritis, systemic lupus erythematosus), HIV, and Alzheimer's and other dementias.Our study cohort included adults aged 20 years or older affiliated with the Fondo Nacional de Salud (FONASA), Chile's national public health insurance program.

Table 3 .
Characteristics of the study cohort of adults aged 20 years or older affiliated to FONASA, with laboratory-confirmed COVID-19, unvaccinated and vaccinated individuals who received an inactivated SARS-CoV-2 vaccine Sinovac primary series plus a heterologous mRNA booster (CC+mRNA) and an additional mRNA booster (fourth dose), August 11, 2021, through August 18, 2022* Notes.*COVID-19 denotes coronavirus disease 2019.The Ministry of Health launched a COVID-19 vaccine first booster campaign in August 11, 2021, and a second booster campaign on February 14, 2022, prioritizing individuals with older age, immunocompromised, and those with comorbidities, including chronic kidney disease, diabetes, cardiovascular disease (hypertension, myocardial infarction), stroke, chronic obstructive pulmonary disease, hematological disease (lymphoma, leukemia, myeloma), autoimmune disease (rheumatoid arthritis, juvenile idiopathic arthritis, systemic lupus erythematosus), HIV, and Alzheimer's and other dementias.Our study cohort included adults aged 20 years or older affiliated with the Fondo Nacional de Salud (FONASA), Chile's national public health insurance program.

Table 4 .
Characteristics of the study cohort of adults aged 20 years or older affiliated to FONASA, with laboratory-confirmed COVID-19, unvaccinated and vaccinated individuals who received an inactivated SARS-CoV-2 vaccine Sinovac primary series plus a homologous booster (CCC) and an additional mRNA booster (fourth dose), August 11, 2021, through August 18, 2022* Notes.*COVID-19 denotes coronavirus disease 2019.The Ministry of Health launched a COVID-19 vaccine first booster campaign in August 11, 2021, and a second booster campaign on February 14, 2022, prioritizing individuals with older age, immunocompromised, and those with comorbidities, including chronic kidney disease, diabetes, cardiovascular disease (hypertension, myocardial infarction), stroke, chronic obstructive pulmonary disease, hematological disease (lymphoma, leukemia, myeloma), autoimmune disease (rheumatoid arthritis, juvenile idiopathic arthritis, systemic lupus erythematosus), HIV, and Alzheimer's and other dementias.Our study cohort included adults aged 20 years or older affiliated with the Fondo Nacional de Salud (FONASA), Chile's national public health insurance program.

Table 5 .
Characteristics of the study cohort of adults aged 20 years or older affiliated to FONASA, with laboratory-confirmed COVID-19, unvaccinated and vaccinated individuals who received an inactivated SARS-CoV-2 vaccine Sinovac primary series plus a heterologous viral-vectored ChAdOx1 booster (CCA) and an additional mRNA booster (fourth dose), August 11, 2021, through August 18, 2022* Notes.*COVID-19denotes coronavirus disease 2019.The Ministry of Health launched a COVID-19 vaccine first booster campaign in August 11, 2021, and a second booster campaign on February 14, 2022, prioritizing individuals with older age, immunocompromised, and those with comorbidities, including chronic kidney disease, diabetes, cardiovascular disease (hypertension, myocardial infarction), stroke, chronic obstructive pulmonary disease, hematological disease (lymphoma, leukemia, myeloma), autoimmune disease (rheumatoid arthritis, juvenile idiopathic arthritis, systemic lupus erythematosus), HIV, and Alzheimer's and other dementias.Our study cohort included adults aged 20 years or older affiliated with the Fondo Nacional de Salud (FONASA), Chile's national public health insurance program.

Table 6 .
Weekly effectiveness against ICU admissions of mRNA-based second vaccine boosters for individuals with four different three-dose background regimes: (i) BNT162b2 primary series plus a homologous booster, a CoronaVac primary series plus (ii) mRNA booster, (iii) homologous booster, or (iv) ChAdOx-1 booster, compared to unvaccinated individuals among adults aged 20 years and older,March 7, 2022, through August 15, 2022*

Table 7 .
Weekly effectiveness against confirmed death of mRNA-based second vaccine boosters for individuals with four different three-dose background regimes: (i) BNT162b2 primary series plus a homologous booster, a CoronaVac primary series plus (ii) mRNA booster, (iii) homologous booster, or (iv) ChAdOx-1 booster, compared to unvaccinated individuals among adults aged20 years  and older, March 7, 2022, through August 15, 2022*